SAN FRANCISCO, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ: HUMA) and certain of its executives are now defendants in a class action lawsuit filed in the U.S. District Court for the ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the ...

Insider activity at Humacyte (HUMA) has drawn attention after a 17% drop in the company’s stock price over the past year. Insiders, including founder Laura Niklason and board member Gordon ...

H.C. Wainwright has recently initiated Humacyte Inc (HUMA) stock to Buy rating, as announced on December 11, 2023, according to Finviz. Earlier, on August 14, 2023, Piper Sandler had raised the stock ...

NEW YORK, Nov. 25, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Humacyte ...

NEW YORK, Nov. 25, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Humacyte, Inc.

Humacyte, Inc. (HUMA) Securities Class Action: The complaint, filed on behalf of investors who purchased Humacyte securities between May 10, 2024, and October 17, 2024, claims that the company and ...

SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ: HUMA) and certain of its executives are now defendants in a class action lawsuit filed in the U.S. District Court for the ...

Humacyte and its consolidated subsidiaries develop and manufacture off-the-shelf, implantable, and bioengineered human tissues. For more information, submit a form , email attorney Aaron Dumas ...